据华尔街日报报道，礼来即将与专门研发治疗炎症性疾病药物的 Ventyx Biosciences, Inc. 达成收购协议，交易金额可能超过 10 亿美元。
受此消息推动，Ventyx Biosciences的股价在盘后交易中上涨了超过60%。
据华尔街日报报道，礼来即将与专门研发治疗炎症性疾病药物的 Ventyx Biosciences, Inc. 达成收购协议，交易金额可能超过 10 亿美元。
受此消息推动，Ventyx Biosciences的股价在盘后交易中上涨了超过60%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.